Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

23,957 total articles

La Rosa Holdings Corp. Reports First Half 2026 Results Highlighted by 10% Gross Profit Growth and 42% Improvement in Operating Loss

La Rosa Holdings Corp. Reports First Half 2026 Results Highlighted by 10% Gross Profit Growth and 42% Improvement in Operating Loss

La Rosa Holdings Corp., a US-based real estate and PropTech company, announced first half 2026 financial results marked by a nearly 10% increase in gross profit to $3.7 million and a 42% reduction in operating loss to $4.2 million compared to the prior year. The company also reported a 25% decrease in operating expenses and a 9.4% improvement in ne…

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851

Lexicon Pharmaceuticals has earned its third $10 million milestone payment in 2026 from Novo Nordisk following successful patient dosing in the Phase 1 trial of LX9851, a novel oral small molecule for obesity and metabolic disorders. This achievement brings total milestone payments to $75 million out of a potential $1 billion collaboration deal. Th…

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

BioCardia, a leader in cellular therapeutics for cardiovascular diseases, announced FDA confirmation of Pre-Submission Meeting minutes for its Helix Transendocardial Delivery Catheter. This ratification supports BioCardia's planned follow-on pre-submission intended to enable Helix's approval via the De Novo regulatory pathway, potentially accelerat…

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026

Amarin Corporation plc announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2026 featuring new analyses from the REDUCE-IT trial and mechanistic EPA data. These presentations cover treatment adherence, long-term outcomes, and biomarker insights related to cardiovascular risk reduction with icosapent ethyl (VASCEPA/V…

Edible Garden and Square Roots Announce Strategic Partnership to Accelerate Farm-to-Formula® Functional Nutrition Platform

Edible Garden and Square Roots Announce Strategic Partnership to Accelerate Farm-to-Formula® Functional Nutrition Platform

Edible Garden AG, a Nasdaq-listed leader in controlled environment agriculture, announced a strategic partnership with Square Roots to develop a new generation of clean-label, functional ready-to-drink beverages. Combining Square Roots' expertise in plant science with Edible Garden's advanced Farm-to-Formula® platform and aseptic manufacturing, the…

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

LEQEMBI IQLIK® (lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer’s Disease

Biogen and Eisai announced US availability of LEQEMBI IQLIK®, a subcutaneous autoinjector for initiation and maintenance therapy of early Alzheimer's disease, offering a more convenient and flexible alternative to intravenous infusion. The treatment, supported by robust clinical trial data demonstrating slowed disease progression and significant co…

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation

Clearmind Medicine Inc., a clinical-stage biotech focused on psychedelic-derived neuroplastogens, announced the U.S. publication of a patent application covering a novel combination of MDMA and N-acylethanolamines such as PEA, aimed at treating PTSD, anxiety, and eating disorders. This comes alongside the FDA's newly finalized guidance for clinical…

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Rhythm Pharmaceuticals announced that Japan's Ministry of Health, Labour and Welfare has approved IMCIVREE® (setmelanotide) to treat patients with acquired hypothalamic obesity (HO), a rare disease characterized by significant weight gain due to hypothalamic injury. Supported by positive Phase 3 trial data, this marks IMCIVREE as the first approved…

Evolution Metals & Technologies Corp. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes

Evolution Metals & Technologies Corp. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® Indexes

Evolution Metals & Technologies Corp. (Nasdaq: EMAT), a U.S.-based critical materials and manufacturing company, announced its preliminary inclusion in FTSE Russell's Russell 3000® and Russell 2000® indexes, effective September 21, 2026, pending final review. This inclusion is anticipated to increase the company's visibility among institutional and…

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program

ASML Holding N.V., a global leader in semiconductor equipment manufacturing, has disclosed recent transactions under its ongoing share buyback program announced in January 2026. Over five consecutive days in August, ASML repurchased a total of approximately 252,684 shares at weighted average prices ranging from €1,506.98 to €1,618.13 per share. The…

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions

Humacyte, Inc. announced that following favorable discussions with the FDA, it intends to file a supplemental Biologics License Application (BLA) in November 2026 to expand approval of its acellular tissue engineered vessel (ATEV) for dialysis access. This follows FDA approval of ATEV for vascular trauma in 2024. The application will be supported b…

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer

AEON Biopharma, listed on NYSE American as AEON, has named Paul Lee, M.D., Ph.D., former Deputy Director at the FDA's Office of Neuroscience, as acting Chief Regulatory Officer. Dr. Lee, who has been advising AEON on regulatory strategy via Clintrex Research LLC, will now lead the company’s interactions with the FDA and oversee the regulatory roadm…

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Erasca, Inc. announced that the FDA has granted Fast Track Designation to its investigational drug ERAS-0015 for metastatic pancreatic adenocarcinoma. The designation is based on promising Phase 1 data demonstrating clinical activity and tolerability in multiple tumor types, including pancreatic and lung cancers. The company plans three potentially…

TTEC RealSkill™ Wins Gold for Best Use of AI for Learning at 2026 Brandon Hall Group™ HCM Excellence Awards

TTEC RealSkill™ Wins Gold for Best Use of AI for Learning at 2026 Brandon Hall Group™ HCM Excellence Awards

TTEC Holdings, Inc. has been awarded the Gold award in the 2026 Brandon Hall Group HCM Excellence Awards for their RealSkill AI-Driven Workforce Readiness program. The program uses AI-powered simulations and personalized coaching to help employees practice and improve customer interaction skills. This recognition highlights TTEC's leadership in app…

Datacentrex Secures Colocation Capacity and Set to Expand Mining Fleet by More Than 500 Additional ElphaPex DG2 Miners

Datacentrex Secures Colocation Capacity and Set to Expand Mining Fleet by More Than 500 Additional ElphaPex DG2 Miners

Datacentrex, Inc. has secured colocation capacity for deployment of more than 500 prepaid ElphaPex DG2 Scrypt ASIC miners, expected to be energized within 30 days. This expansion will increase the company's aggregate hashrate by approximately 21%, improving fleet energy efficiency without additional capital expenditure. The deployment aligns with i…

NANO Nuclear and Tillman Digital Gateway Sign Strategic Commercial Framework to Enable Advanced Nuclear Power for Gigawatt-Scale U.S. AI Industrial Zones

NANO Nuclear and Tillman Digital Gateway Sign Strategic Commercial Framework to Enable Advanced Nuclear Power for Gigawatt-Scale U.S. AI Industrial Zones

NANO Nuclear Energy Inc. announced a strategic commercial framework agreement with Tillman Global Holdings to provide advanced nuclear reactor technology to power Tillman's planned gigawatt-scale AI industrial zones across the U.S. The companies aim to deploy 2 GW or more of advanced nuclear capacity by the mid-2030s and 6 GW or more by 2040, utili…